Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)

Next Previous
Trial Profile

An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Traumatic brain injuries
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms CHIC
  • Sponsors Abliva

Most Recent Events

  • 04 Oct 2018 According to a NeuroVive Pharmaceutical media release, biomarker analyses using samples from this study patients has been completed.
  • 04 Oct 2018 Results of biomarker analyses using samples from this study patients, presented in a NeuroVive Pharmaceutical media release.
  • 15 Feb 2018 According to a NeuroVive Pharmaceuticals media release, the company expects presentation of complete results from this trial in 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top